Oteseconazole Capsules approved for marketing by China NMPA

Recently, the Category 1 innovative drug Oteseconazole Capsules of eVENUS PHARMACEUTICAL LABORATORIES INC. is approved by China NMPA. It is indicated for the treatment of severe vulvovaginal candidiasis (VVC).

The approval of oteseconazole capsules for the treatment of severe VVC in China is an important milestone under Mycovia’s exclusive agreement with Hengrui to develop and commercialize oteseconazole in China, including Mainland China, Hong Kong, Macau and Taiwan, for the treatment or prevention of a range of fungal conditions.

Oteseconazole, sold under the brand name Vivjoa, is a medication used for the treatment of vaginal yeast infections. It was approved for medical use in the United States in April 2022. It was developed by Mycovia Pharmaceuticals.